NO312726B1 - Enterokinetisk benzamid - Google Patents

Enterokinetisk benzamid Download PDF

Info

Publication number: NO312726B1
Authority: NO; Norway
Prior art keywords: compound according; compound; formula; drug; preparation
Prior art date: 1994-11-24

Application number

NO19972143A

Other languages

English (en)

Norwegian (no)

Other versions

NO972143L (no

NO972143D0 (no

Inventor

Georges Henri Paul Van Daele

Jean-Paul Rene Marie A Bosmans

Joannes Adrianus Jac Schuurkes

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-24

Filing date

1997-05-09

Publication date

2002-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8217407&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO312726(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-05-09 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1997-05-09 Publication of NO972143L publication Critical patent/NO972143L/no

1997-05-09 Publication of NO972143D0 publication Critical patent/NO972143D0/no

2002-06-24 Publication of NO312726B1 publication Critical patent/NO312726B1/no

Links

KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
150000001875 compounds Chemical class 0.000 claims description 75
210000001072 colon Anatomy 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 9
230000000968 intestinal effect Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
239000002585 base Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
-1 sulfonyloxy group Chemical group 0.000 claims description 5
206010021333 Ileus paralytic Diseases 0.000 claims description 4
KKMOQGWTJRGLNN-UHFFFAOYSA-N 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;hydrochloride Chemical compound Cl.C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 KKMOQGWTJRGLNN-UHFFFAOYSA-N 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
239000012442 inert solvent Substances 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
QZRSNVSQLGRAID-UHFFFAOYSA-N 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;butanedioic acid Chemical compound OC(=O)CCC(O)=O.C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 QZRSNVSQLGRAID-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
206010010774 Constipation Diseases 0.000 claims description 2
239000003513 alkali Substances 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
230000003111 delayed effect Effects 0.000 claims description 2
239000012458 free base Substances 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
230000002980 postoperative effect Effects 0.000 claims description 2
208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
229940100198 alkylating agent Drugs 0.000 claims 1
239000002168 alkylating agent Substances 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
239000000203 mixture Substances 0.000 description 24
239000000243 solution Substances 0.000 description 24
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
230000004044 response Effects 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000002244 precipitate Substances 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
230000008602 contraction Effects 0.000 description 8
230000004899 motility Effects 0.000 description 8
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 7
241000700199 Cavia porcellus Species 0.000 description 7
229940125900 compound 59 Drugs 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
229940125904 compound 1 Drugs 0.000 description 6
230000004936 stimulating effect Effects 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
239000008188 pellet Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000036461 convulsion Effects 0.000 description 4
210000003405 ileum Anatomy 0.000 description 4
210000002429 large intestine Anatomy 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
ZPMNHBXQOOVQJL-UHFFFAOYSA-N prucalopride Chemical compound C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 ZPMNHBXQOOVQJL-UHFFFAOYSA-N 0.000 description 4
229960005137 succinic acid Drugs 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960001701 chloroform Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000011597 hartley guinea pig Methods 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
230000001129 nonadrenergic effect Effects 0.000 description 3
230000002536 noncholinergic effect Effects 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
HIXAJGFVNMKLML-UHFFFAOYSA-N 1-(3-methoxypropyl)piperidin-4-amine Chemical compound COCCCN1CCC(N)CC1 HIXAJGFVNMKLML-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
KRMUVKSAOVLXLF-UHFFFAOYSA-N 4-amino-5-chloro-2,3-dihydro-1-benzofuran-7-carboxylic acid Chemical compound C1=C(Cl)C(N)=C2CCOC2=C1C(O)=O KRMUVKSAOVLXLF-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
230000006181 N-acylation Effects 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 2
210000001815 ascending colon Anatomy 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
230000009989 contractile response Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000005176 gastrointestinal motility Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000008991 intestinal motility Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
YGTVRIJNXGNYDR-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxy 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OOS(=O)(=O)C1=CC=C(C)C=C1 YGTVRIJNXGNYDR-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BQLHMMQUVJCTAN-UHFFFAOYSA-N 1-chloro-3-methoxypropane Chemical compound COCCCCl BQLHMMQUVJCTAN-UHFFFAOYSA-N 0.000 description 1
LUSQWZJVTISPFN-UHFFFAOYSA-N 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;hydrate Chemical compound O.C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 LUSQWZJVTISPFN-UHFFFAOYSA-N 0.000 description 1
ARFCANNJTSJXLS-UHFFFAOYSA-N 4-amino-5-chloro-n-piperidin-4-yl-2,3-dihydro-1-benzofuran-7-carboxamide Chemical compound C1=C(Cl)C(N)=C2CCOC2=C1C(=O)NC1CCNCC1 ARFCANNJTSJXLS-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
NQOQNAKUPWEYPX-WNQIDUERSA-N C[C@H](O)C(O)=O.C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 Chemical compound C[C@H](O)C(O)=O.C1CN(CCCOC)CCC1NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2 NQOQNAKUPWEYPX-WNQIDUERSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102000003834 Histamine H1 Receptors Human genes 0.000 description 1
108090000110 Histamine H1 Receptors Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
238000003287 bathing Methods 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
108010070955 beta C receptor Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000004600 colonic motility Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
XJPAEZVERBCSTJ-UHFFFAOYSA-N methylsulfonyloxy methanesulfonate Chemical compound CS(=O)(=O)OOS(C)(=O)=O XJPAEZVERBCSTJ-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000036316 preload Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012048 reactive intermediate Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000002586 relaxatory effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004544 spot-on Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
238000001665 trituration Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO19972143A 1994-11-24 1997-05-09 Enterokinetisk benzamid NO312726B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP94203421		1994-11-24
PCT/EP1995/004519 WO1996016060A1 (en)	1994-11-24	1995-11-16	Enterokinetic benzamide

Publications (3)

Publication Number	Publication Date
NO972143L NO972143L (no)	1997-05-09
NO972143D0 NO972143D0 (no)	1997-05-09
NO312726B1 true NO312726B1 (no)	2002-06-24

Family

ID=8217407

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19972143A NO312726B1 (no)	1994-11-24	1997-05-09	Enterokinetisk benzamid
NO2010003C NO2010003I2 (no)	1994-11-24	2010-03-05	Prukaloprid eller et farmasøytisk aksepterbart syreaddisjonssalt derav
NO2019044C NO2019044I1 (no)	1994-11-24	2019-12-11	Dihydrobenzofurancarboksamid - forlenget SPC

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2010003C NO2010003I2 (no)	1994-11-24	2010-03-05	Prukaloprid eller et farmasøytisk aksepterbart syreaddisjonssalt derav
NO2019044C NO2019044I1 (no)	1994-11-24	2019-12-11	Dihydrobenzofurancarboksamid - forlenget SPC

Country Status (40)

Country	Link
US (3)	US5854260A (xx)
EP (1)	EP0807110B1 (xx)
JP (1)	JP3046076B2 (xx)
KR (1)	KR100233489B1 (xx)
CN (1)	CN1071332C (xx)
AP (1)	AP777A (xx)
AR (1)	AR001769A1 (xx)
AT (1)	ATE217306T1 (xx)
AU (1)	AU704043B2 (xx)
BG (1)	BG63710B1 (xx)
BR (1)	BRPI9509819B8 (xx)
CA (1)	CA2205573C (xx)
CY (2)	CY2296B1 (xx)
CZ (1)	CZ292847B6 (xx)
DE (2)	DE69526679T2 (xx)
DK (1)	DK0807110T3 (xx)
EE (1)	EE03313B1 (xx)
ES (1)	ES2177671T3 (xx)
FI (1)	FI120147B (xx)
FR (1)	FR10C0001I2 (xx)
HR (1)	HRP950571B1 (xx)
HU (1)	HU226560B1 (xx)
IL (1)	IL116101A (xx)
LU (1)	LU91644I2 (xx)
MY (1)	MY112944A (xx)
NL (1)	NL300435I1 (xx)
NO (3)	NO312726B1 (xx)
NZ (1)	NZ297753A (xx)
OA (1)	OA10422A (xx)
PL (1)	PL183713B1 (xx)
PT (1)	PT807110E (xx)
RO (1)	RO116279B1 (xx)
RU (1)	RU2154643C2 (xx)
SI (1)	SI0807110T1 (xx)
SK (1)	SK283499B6 (xx)
TR (1)	TR199501483A2 (xx)
TW (1)	TW490465B (xx)
UA (1)	UA59334C2 (xx)
WO (1)	WO1996016060A1 (xx)
ZA (1)	ZA959996B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW490465B (en) *	1994-11-24	2002-06-11	Janssen Pharmaceutica Nv	Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
TW402591B (en) *	1997-07-11	2000-08-21	Janssen Pharmaceutica Nv	Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
CA2332275A1 (en) *	1998-05-14	1999-11-18	Zoltan Tamas Nagy	Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
CA2352278A1 (en) *	1998-11-23	2000-06-02	Janssen Pharmaceutica, N.V.	Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
TW592709B (en) *	1999-04-29	2004-06-21	Janssen Pharmaceutica Nv	Prucalopride oral solution
CN1288730A (zh) *	1999-09-07	2001-03-28	麦克内尔-Ppc股份有限公司	轻泻组合物
AU2003206722B2 (en) *	2002-01-16	2008-01-24	Mercury Pharma Group Limited	Prucalopride-N-oxide
TW201118084A (en) *	2009-09-18	2011-06-01	Adolor Corp	The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
GB201103397D0 (xx)	2011-02-28	2011-04-13	Shire Movetis N V
CN102295594B (zh) *	2011-07-12	2016-01-20	上海医药工业研究院	4-n-取代-1-(3-甲氧基丙基)-4-哌啶胺类化合物及制备和应用
WO2013024164A1 (en)	2011-08-18	2013-02-21	Shire Ag	Combinations of a 5-ht4 receptor agonist and a pde4 inhibitor for use in therapy
EP3413891B1 (en)	2016-02-11	2024-01-03	Symed Labs Limited	Processes for the preparation of highly pure prucalopride succinate
CN108727351B (zh) *	2017-04-19	2021-08-31	鲁南制药集团股份有限公司	一种普芦卡必利的精制方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5374637A (en) *	1989-03-22	1994-12-20	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) *	1990-03-06	1990-05-02	Janssen Pharmaceutica Nv	N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
TW490465B (en) *	1994-11-24	2002-06-11	Janssen Pharmaceutica Nv	Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof

1995
- 1995-11-08 TW TW084111813A patent/TW490465B/zh not_active IP Right Cessation
- 1995-11-16 ES ES95941613T patent/ES2177671T3/es not_active Expired - Lifetime
- 1995-11-16 UA UA97052121A patent/UA59334C2/uk unknown
- 1995-11-16 PL PL95320297A patent/PL183713B1/pl unknown
- 1995-11-16 CN CN95196347A patent/CN1071332C/zh not_active Expired - Lifetime
- 1995-11-16 HU HU9702127A patent/HU226560B1/hu active Protection Beyond IP Right Term
- 1995-11-16 EE EE9700116A patent/EE03313B1/xx not_active IP Right Cessation
- 1995-11-16 NZ NZ297753A patent/NZ297753A/en not_active IP Right Cessation
- 1995-11-16 AP APAP/P/1997/000992A patent/AP777A/en active
- 1995-11-16 AU AU42992/96A patent/AU704043B2/en not_active Expired
- 1995-11-16 DE DE69526679T patent/DE69526679T2/de not_active Expired - Lifetime
- 1995-11-16 BR BRPI9509819A patent/BRPI9509819B8/pt not_active IP Right Cessation
- 1995-11-16 EP EP95941613A patent/EP0807110B1/en not_active Expired - Lifetime
- 1995-11-16 DE DE201012000002 patent/DE122010000002I1/de active Pending
- 1995-11-16 JP JP8516549A patent/JP3046076B2/ja not_active Expired - Lifetime
- 1995-11-16 WO PCT/EP1995/004519 patent/WO1996016060A1/en active IP Right Grant
- 1995-11-16 US US08/836,276 patent/US5854260A/en not_active Expired - Lifetime
- 1995-11-16 RO RO97-00942A patent/RO116279B1/ro unknown
- 1995-11-16 SK SK652-97A patent/SK283499B6/sk not_active IP Right Cessation
- 1995-11-16 CZ CZ19971555A patent/CZ292847B6/cs not_active IP Right Cessation
- 1995-11-16 DK DK95941613T patent/DK0807110T3/da active
- 1995-11-16 RU RU97110232/04A patent/RU2154643C2/ru active
- 1995-11-16 AT AT95941613T patent/ATE217306T1/de active
- 1995-11-16 PT PT95941613T patent/PT807110E/pt unknown
- 1995-11-16 KR KR1019970703419A patent/KR100233489B1/ko not_active IP Right Cessation
- 1995-11-16 SI SI9530593T patent/SI0807110T1/xx unknown
- 1995-11-16 CA CA002205573A patent/CA2205573C/en not_active Expired - Lifetime
- 1995-11-23 ZA ZA959996A patent/ZA959996B/xx unknown
- 1995-11-23 IL IL11610195A patent/IL116101A/xx not_active IP Right Cessation
- 1995-11-23 HR HR950571A patent/HRP950571B1/xx not_active IP Right Cessation
- 1995-11-23 AR AR33436095A patent/AR001769A1/es unknown
- 1995-11-24 MY MYPI95003617A patent/MY112944A/en unknown
- 1995-11-24 TR TR95/01483A patent/TR199501483A2/xx unknown
1997
- 1997-05-09 NO NO19972143A patent/NO312726B1/no not_active IP Right Cessation
- 1997-05-23 FI FI972203A patent/FI120147B/fi active Protection Beyond IP Right Term
- 1997-05-23 OA OA70012A patent/OA10422A/en unknown
- 1997-06-11 BG BG101605A patent/BG63710B1/bg unknown
1998
- 1998-09-24 US US09/159,993 patent/US5948794A/en not_active Expired - Lifetime
1999
- 1999-06-04 US US09/325,865 patent/US6310077B1/en not_active Expired - Lifetime
2002
- 2002-09-20 CY CY0200055A patent/CY2296B1/xx unknown
2010
- 2010-01-06 FR FR10C0001C patent/FR10C0001I2/fr active Active
- 2010-01-15 CY CY2010001C patent/CY2010001I1/el unknown
- 2010-01-27 LU LU91644C patent/LU91644I2/en unknown
- 2010-02-09 NL NL300435C patent/NL300435I1/nl unknown
- 2010-03-05 NO NO2010003C patent/NO2010003I2/no unknown
2019
- 2019-12-11 NO NO2019044C patent/NO2019044I1/no unknown

Also Published As

Publication number	Publication date
SK283499B6 (sk)	2003-08-05
TW490465B (en)	2002-06-11
NO2010003I1 (no)	2010-03-05
PL183713B1 (pl)	2002-07-31
BRPI9509819B8 (pt)	2021-07-06
AU704043B2 (en)	1999-04-15
CA2205573A1 (en)	1996-05-30
BG63710B1 (bg)	2002-10-31
ZA959996B (en)	1997-05-23
JPH09512832A (ja)	1997-12-22
LU91644I2 (en)	2010-03-29
CA2205573C (en)	2006-05-09
PT807110E (pt)	2002-10-31
DK0807110T3 (da)	2002-09-02
CZ292847B6 (cs)	2003-12-17
AP777A (en)	1999-10-28
PL320297A1 (en)	1997-09-15
CN1164233A (zh)	1997-11-05
US5854260A (en)	1998-12-29
EE03313B1 (et)	2000-12-15
BRPI9509819B1 (pt)	2018-05-15
MX9703869A (es)	1997-09-30
OA10422A (en)	2002-03-19
KR100233489B1 (ko)	1999-12-01
DE69526679T2 (de)	2002-12-05
IL116101A0 (en)	1996-01-31
RU2154643C2 (ru)	2000-08-20
FR10C0001I1 (xx)	2010-02-12
IL116101A (en)	1999-08-17
BR9509819A (pt)	1997-09-30
HU226560B1 (en)	2009-04-28
CY2010001I2 (el)	2010-07-28
WO1996016060A1 (en)	1996-05-30
AU4299296A (en)	1996-06-17
BG101605A (en)	1998-02-27
FI120147B (fi)	2009-07-15
SI0807110T1 (en)	2002-08-31
RO116279B1 (ro)	2000-12-29
JP3046076B2 (ja)	2000-05-29
HRP950571A2 (en)	1997-08-31
CN1071332C (zh)	2001-09-19
FI972203A (fi)	1997-05-23
DE122010000002I1 (de)	2011-12-01
AR001769A1 (es)	1997-12-10
NO972143L (no)	1997-05-09
US5948794A (en)	1999-09-07
ATE217306T1 (de)	2002-05-15
EP0807110B1 (en)	2002-05-08
NZ297753A (en)	1998-05-27
NO2010003I2 (no)	2012-08-27
CZ155597A3 (en)	1997-09-17
US6310077B1 (en)	2001-10-30
NL300435I1 (nl)	2010-04-01
DE69526679D1 (de)	2002-06-13
EP0807110A1 (en)	1997-11-19
FR10C0001I2 (fr)	2011-04-01
FI972203A0 (fi)	1997-05-23
ES2177671T3 (es)	2002-12-16
NO972143D0 (no)	1997-05-09
SK65297A3 (en)	1997-10-08
CY2296B1 (en)	2003-07-04
AP9700992A0 (en)	1997-07-31
HUT77375A (hu)	1998-04-28
UA59334C2 (uk)	2003-09-15
CY2010001I1 (el)	2010-07-28
TR199501483A2 (tr)	1996-07-21
NO2019044I1 (no)	2019-12-11
MY112944A (en)	2001-10-31
HRP950571B1 (en)	2001-12-31

Legal Events

Date	Code	Title	Description
2010-03-22	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: PREPARATNAVN: RESOLOR 1; NAT. REG. NO/DATE: EU/1/09/581/001/NO 20091214; FIRST REG. NO/DATE: EU/1/09/581/001 20080528 Spc suppl protection certif: 2010003 Filing date: 20100305
2012-08-27	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: PREPARATNAVN: RESOLOR 1; NAT. REG. NO/DATE: EU/1/09/581/001/NO 20091214; FIRST REG. NO/DATE: EU/1/09/581/001 20080528 Spc suppl protection certif: 2010003 Filing date: 20100305 Extension date: 20201116
2015-11-23	MK1K	Patent expired
2019-11-25	SPCS	Change of name or address of the owner of a supplementary protection certificate	Owner name: SHIRE INTERNATIONAL GMBH, CH Spc suppl protection certif: 2010003
2019-12-23	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: DIHYDROBENZOFURANCARBOKSA MID - FORLENGET SPC; REG. NO/DATE: EU/1/09/581/001 20091214 Spc suppl protection certif: 2019044 Filing date: 20191211
2020-12-07	SPCX	Expiry of an spc	Free format text: PRODUCT NAME: PRUKALOPRID ELLER ET FARMASOEYTISK AKSEPTERBART SYREADDISJONSSALT DERAV Spc suppl protection certif: 2010003 Effective date: 20201116

Publication	Publication Date	Title
JPS60169476A (ja)	1985-09-02	新規のピリジン−２−エ−テル、その製造法及び該化合物を含有する、鎮痛作用を有する医薬品
NO312726B1 (no)	2002-06-24	Enterokinetisk benzamid
NO314662B1 (no)	2003-04-28	Gastrokinetiske monocykliske benzamider av 3- eller 4- substituerte 4-(aminometyl)-piperidinderivater
WO1999032481A1 (en)	1999-07-01	Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2502343B2 (ja)	1996-05-29	薬学的に活性な置換ベンズアミド
DE69721742T2 (de)	2004-03-11	N-substituierte 4-((4'-aminobenzoyl)-oxymethyl)-piperidine mit gastrokinetischen eigenschaften
CZ91897A3 (en)	1997-12-17	Derivatives of n-substituted piperidinyl bicyclic benzoates
DE2513136A1 (de)	1975-10-02	Aromatische amide heterocyclischer verbindungen
RU2154634C2 (ru)	2000-08-20	Производные фенил-оксо-алкил-(4-пиперидинил) бензоата, способы их получения, фармацевтическая композиция на их основе и способ ее получения и промежуточное соединение
NO311673B1 (no)	2002-01-02	Fenyl-okso-alkyl-(4-piperidinyl)benzoatderivater
KR100388253B1 (ko)	2003-10-04	N-치환된피페리디닐바이사이클릭벤조에이트유도체
TW448173B (en)	2001-08-01	N-substituted piperidinyl bicyclic benzoate derivatives
MXPA97003869A (en)	1998-07-03	Benzamida enterocinet
MXPA97002363A (es)	1998-07-03	Derivados biciclicos de benzoato de piperidinilon-substituidos
MXPA97002356A (en)	1998-07-03	Derivatives of phenyl-oxy-alkyl- (4-piperidinyl) benzo
NO160443B (no)	1989-01-09	Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.